Reference:
1. Fereidan-Esfahani M, Mahmudi F, Jahansouz M, Weber MS, Rodriguez M. Biomarkers in radiologically isolated syndrome: The missing piece in the puzzle of treatment indication? Journal of the neurological sciences. 2017;375:129.
2. Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, et al. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Multiple Sclerosis and Related Disorders. 2023;73:104677.
3. Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017;13:871-9.
4. Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C. Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. Front Pharmacol. 2022;13:832048.
5. Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299-305.